Clinical management of TP53 mosaic variants found on germline genetic testing.
Cancer Genet
; 284-285: 43-47, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38677009
ABSTRACT
BACKGROUND:
Germline heterozygous TP53 pathogenic variants (PVs) cause Li Fraumeni Syndrome (LFS, OMIM#151623). TP53 PVs at lower-than-expected variant allele frequencies (VAF) may reflect postzygotic mosaicism (PZM) or clonal hematopoiesis (CH); however, no guidelines exist for workup and clinical management. PATIENTS ANDMETHODS:
Retrospective analysis of probands who presented to an academic cancer genetics program with a TP53 PV result on germline genetic testing.RESULTS:
Twenty-one of 125 unrelated probands (17 %) were found to harbor a TP53 PV with VAF<30 % or a designation of "mosaic". A diagnosis of PZM was made in nine (43 %) due to a clinical phenotype consistent with LFS with (n = 8) or without (n = 1) positive ancillary tissue testing. Twelve patients (57 %) were diagnosed with presumed CH (pCH) due to a diagnosis of a myeloproliferative neoplasm, negative ancillary tissue testing, clinical phenotype not meeting LFS criteria, no cancer, and/or no first cancer age<50. Of the 19 patients with biological offspring, nine had either partial or complete offspring testing, all negative.CONCLUSIONS:
Determining the etiology of low VAF TP53 PVs requires ancillary tissue testing and incorporation of clinical phenotype. Discerning PZM versus CH is important to provide optimal care and follow-up.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Pruebas Genéticas
/
Proteína p53 Supresora de Tumor
/
Síndrome de Li-Fraumeni
/
Mutación de Línea Germinal
/
Mosaicismo
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Genet
/
Cancer genetics (Online)
/
Cancer genetics (Print)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos